Investments
Inflexion and Informa combine FBX, Novantas
Inflexion and Novantas will each own a minority stake in the newly formed financial data business
DACH buyouts continue recovery from Q2 2020 low
Both deal volume and value are now back on par with the figures for Q4 2019, prior to the pandemic
Paragon-backed Apontis Pharma announces IPO intention
Paragon acquired the pharmaceutical business from its parent company UCB in 2018 via Paragon II
Hg's MeinAuto announces intention to float
Hg invested in the new car sales platform in 2018; prior backers included HV Capital and DN Capital
PE-backed diagnostics firm Synlab announces IPO pricing
Shares will be priced at €18-23, equating to a €4-5bn market capitalisation and €5.9-6.9bn EV
Buyout rankings: who invested the most in Europe in Q1 2021?
Unquote tallies the top 10 most active GPs across the European buyout space in the first quarter
PE players seek opportunities in minority deals, differentiated strategies
Minority investments, co-investments and other creative deals made via differentiated strategies could become even more relevant post-pandemic
Q&A: Debevoise's Bet-Mansour and Scoville on Spacs' relevance for PE
The partners share their thoughts on why Spacs are so attractive, what sponsors should be wary of, and whether they expect a similar uptake in Europe
3i's Carnimolla and Howard on investing in naturality businesses
With a significant increase in the number of people focusing on their physical and mental wellbeing, 3i sees growing opportunities for PE
Register for the Growth Equity virtual event
Leading industry participants will discuss the outlook for growth equity on Thursday 22 April
PE-backed Synlab announces IPO intention
Cinven, Novo Holdings and OTTP hold stakes in the Germany-based laboratory diagnostics group
Unquote Private Equity Podcast: Ravenous for recurring revenue
The Unquote Private Equity Podcast is back to its regular format this week, with the team looking at PE's appetite for recurring revenue models
Q4 Barometer: How European activity returned to pre-pandemic level
European PE deal value staged an impressive recovery over the course of 2020, capped by a busy Q4
Back to school: education dealflow heats up as pandemic settles
Digital opportunities and long-term growth drivers have resulted in an influx of deals in recent weeks, with more in the pipeline
ICG invests in $80m round for Eliem Therapeutics
This is the first investment made by ICG Life Sciences, which was launched in January 2021
Podcast: In conversation with... Jan Kengelbach, BC Partners
Portfolio operations partner Kengelbach shares his experience and lessons learned from getting hands-on with portfolio company Aenova
Unquote Private Equity Podcast: the price is right?
Following the publication of the Q4 2020 Multiples Heatmap, Unquote welcomes Clearwater's executive team to discuss pricing trends
The Deals Pipeline
A highlight of deal processes underway and involving PE, either on the buy- or sell-side, across Europe
Quantifying PE's appetite for recurring revenue models
Buyouts in sectors where recurring revenue models are predominant went from 8% of European volume in 2010 to 22% in 2021 to date
Sharp focus on top assets boosts average multiple in consumer sector
Covid-resilient assets are the only ones coming to market, with suitably hefty price tags, says Clearwater's O'Donnell
How UK PE buyouts soared ahead of 2021 Budget
Amount of dealflow in the past three months is significantly higher than in previous December-February periods
Nordic players await distressed carve-out uptick
Carve-out activity in the Nordic region hit a three-year low last year, but was still propped up mainly by corporates divesting healthy assets
Biotech market provides dose of optimism
In the past year, the biotech market has seen buoyant activity, reaching record levels of investments
No need to panic about high dry powder as PE market comes roaring back, says Bain
Appetite remains high for deal-making and exits, according to Bain & Company’s 2021 Global Private Equity Report